Clinical, Cosmetic and Investigational Dermatology (Nov 2022)
Recalcitrant Palmar-Plantar Atopic Dermatitis Successfully Treated with Dupilumab: A Case Series
Abstract
Lin Deng,1,* Yingzhi Luo,1,* Binyi An,2 Ming Su,1 Hong Sang,3 Fang Liu3 1Department of Dermatology, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou, 310006, People’s Republic of China; 2Department of Dermatology, Jinling Hospital, Nanjing Medical University, Nanjing, 210002, People’s Republic of China; 3Department of Dermatology, Jinling Hospital, Medical School of Nanjing University, Nanjing, 210002, People’s Republic of China*These authors contributed equally to this workCorrespondence: Fang Liu; Hong Sang, Department of Dermatology, Jinling Hospital, Medical School of Nanjing University, Nanjing, 210002, People’s Republic of China, Tel +86-25-80860092, Fax +86-25-84815775, Email [email protected]; [email protected]: Palmar-plantar atopic dermatitis is a common and debilitating condition with significant diagnostic and management challenges.Case Presentation: The paper presents the successful treatment of dupilumab in five female patients with recalcitrant palmar-plantar atopic dermatitis.Methods: The Hand Eczema Severity Index (HECSI) and the Foot Eczema Severity Index (FECSI), eosinophils and IgE levels were evaluated before and after the treatment.Results: Five recalcitrant palmar-plantar atopic dermatitis patients had substantial responses to dupilumab and the persistent pruritus was soon alleviated during the therapy. By week 16, all patients’ palmar-plantar eczema has been almost clear, with significant decrease of HECSI and FECSI. The count of eosinophils and IgE levels returned to normal in all patients.Conclusion: Dupilumab significantly improves disease severity and reduces eosinophils and IgE in refractory palmar-plantar AD patients.Keywords: atopic dermatitis, dupilumab, palmar-plantar
